Auxilium Pharmaceuticals Upgraded To Buy By MKM, $26 PT

In a report issued Wednesday, MKM Partners upgraded its rating of Auxilium Pharmaceuticals Inc.

from Neutral to Buy with a target price of $26. Analyst Jon LeCroy sees that Testim stabilization and Stendra growth will have a positive impact on the company. LeCroy also estimates an EPS of $0.22 for 2015 and $0.24 for 2016. In addtion data from other drugs in the testing phase should also help boost the company's outlook. Shares of Auxilium Pharmaceuticals are up 1.29 percent to $22.83 in response to today's upgrade by MKM.